Kehoe Law Firm, P.C. Investigating Potential Claims On Behalf Of Individuals Affected By The Cencora Data Breach  

Client Pharmaceutical Companies Reportedly Have Notified State Attorneys General About the Cencora Data Breach

The HIPAA Journal has reported that “Cencora, Inc. (formerly AmerisourceBergen), and its Lash Group affiliate, have been affected by a cyberattack. Cencora announced the attack in a February 2024 filing with the Securities and Exchange Commission (SEC); however, at that point, the extent of the data breach had yet to be determined although Cencora did confirm in the SEC filing that data was exfiltrated in the attack.”

The HIPAA Journal also reported that “[l]ast week, clients of Cencora and The Lash Group started notifying state Attorneys General about the data breach. The total number of affected clients has not yet been confirmed but the breach is known to have affected at least 15 pharmaceutical companies and involved the theft of the personal data of hundreds of thousands of individuals.”

The HIPAA Journal reported that the following pharmaceutical companies have been affected, according to notifications sent to various state Attorneys General: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Bayer Corporation; Bristol Myers Squibb Company and Bristol Myers Squibb Patient Assistance Foundation; Dendreon Pharmaceuticals LLC; Endo Pharmaceuticals Inc.; Genentech, Inc.; GlaxoSmithKline Group of Companies and the GlaxoSmithKline Patient Access Programs Foundation; Incyte Corporation; Marathon Pharmaceuticals, LLC/PTC Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pharming Healthcare, Inc.; Regeneron Pharmaceuticals, Inc; Sumitomo Pharma America, Inc. / Sunovion Pharmaceuticals Inc; and Tolmar. 

Additionally, according to The HIPAA Journal, “[o]n April 10, 2024, Cencora confirmed that the stolen data included first names, last names, addresses, dates of birth, health diagnoses, and/or medications and prescriptions.”

TO LEARN MORE ABOUT THE CENCORA DATA BREACH INVESTIGATION, PLEASE CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], FOR A FREE, NO-OBLIGATION EVALUATION OF POTENTIAL LEGAL CLAIMS.

Cencora Data Breach Reportedly Involving Personal and Sensitive Medical Information  

Kehoe Law Firm, P.C. is investigating potential claims on behalf of individuals affected by a data breach reported by Cencora, Inc. (“Cencora”)

Cencora previously reported that “[o]n February 21, 2024, Cencora . . . learned that data from its information systems had been exfiltrated, some of which may contain personal information.”

On May 24, 2024, Techcrunch.com reported that “U.S. pharmaceutical giant Cencora says it is notifying affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year.”

Techcrunch.com also reported that “[i]n letters to affected individuals sent out this week, Cencora said that the data from its systems includes patient names, their postal address and date of birth, as well as information about their health diagnosis and medications.”

Additionally, TechCrunch.com reported that “[a]ccording to the public data breach notifications filed by Cencora with U.S. state authorities, which TechCrunch has seen, Cencora has so far notified about half a million individuals since learning of the data breach. The number of individuals affected by the Cencora data breach is expected to be far higher. Cencora says on its website that it has served at least 18 million patients to date.”

TO LEARN MORE ABOUT THE CENCORA DATA BREACH INVESTIGATION, PLEASE CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], FOR A FREE, NO-OBLIGATION EVALUATION OF POTENTIAL LEGAL CLAIMS.

bluebird bio Reports Certain Financial Statements Should No Longer Be Relied Upon And Substantial Doubt Regarding Its Ability To Continue As A Going Concern 

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or the “Company”) (NASDAQ: BLUE).

INVESTORS OF BLUEBIRD BIO STOCK WITH FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C.

On March 26, 2024, bluebird bio reported that “[w]hen the Company files its Annual Report on Form 10-K for the year ended December 31, 2023. . ., it expects to continue to report that there is substantial doubt regarding its ability to continue as a going concern.”

bluebird bio also reported that “[o]n March 24, 2024, the Audit Committee of the Board of Directors . . .  of the Company, based on the recommendation of management and after consultation with [Ernst & Young LLP], concluded that the Company’s previously-issued audited consolidated financial statements for each fiscal year beginning January 1, 2019 and its previously-issued unaudited interim condensed consolidated financial statements for each of the first three quarters in such years, as well as the associated earnings releases and investor presentations or other communications describing such financial statements, were materially misstated and, accordingly, should no longer be relied upon.”

On this news, bluebird bio stock was down more than 13% at the open of the market on March 26, 2024.

BLUEBIRD BIO INVESTORS WITH FINANCIAL LOSSES ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE SECURITIES INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Luna Innovations Reports That Certain Financial Statements Should No Longer Be Relied Upon And Will Be Restated – Investors Who Lost Money Encouraged To Contact Kehoe Law Firm, P.C. 

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Luna Innovations Incorporated (“Luna Innovations” or the “Company”) (NASDAQ: LUNA). 

INVESTORS OF LUNA INNOVATIONS STOCK WITH FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C.

Luna Innovations reported that “. . . on March 12, 2024, the Audit Committee . . . of the Board . . . concluded that the Company’s previously issued unaudited interim condensed consolidated financial statements for the quarters ended June 30, 2023, and September 30, 2023, as previously filed with the Securities and Exchange Commission . . . should no longer be relied upon and should be restated.”

Luna Innovations also reported that “. . . the Company has identified material weaknesses in its internal control over financial reporting that existed as of June 30, 2023, and September 30, 2023, and has re-evaluated the effectiveness of the Company’s disclosure controls and procedures as of those dates. Based on this assessment, the Company’s disclosure controls and procedures were ineffective for the quarters ended June 30, 2023, and September 30, 2023.”

On this news, shares of Luna Innovations stock traded down more than 16% in aftermarket trading on March 12, 2024.

LUNA INNOVATIONS INVESTORS WITH FINANCIAL LOSSES ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE SECURITIES INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

Chemours Stock Drops – Company Execs Placed on Administrative Leave – Chemours Investors With Financial Losses Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of The Chemours Company (“Chemours”) (NYSE: CC).

INVESTORS OF CHEMOURS STOCK WITH FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C.

On February 28, 2024, the Board of Directors of Chemours placed President and CEO Mark Newman and other executives on administrative leave pending completion of an Audit Committee review of accounting practices.

On February 29, 2024, Chemours reported that it “. . . has determined that it is unable to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 . . . without unreasonable effort or expense . . ..”

On this news, shares of Chemours stock were down more than 30% during intraday trading on February 29, 2024.

SHAREHOLDERS OF CHEMOURS ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE SECURITIES INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

Investors of Agiliti Stock Encouraged to Contact Kehoe Law Firm, P.C. – AGTI

Kehoe Law Firm, P.C. is investigating the proposed merger agreement where an affiliate of private equity firm Thomas H. Lee Partners, L.P. (“THL”) will acquire all the outstanding shares of Agiliti, Inc. (“Agiliti”) (NYSE: AGTI) common stock not currently owned by THL and its affiliates and certain management shareholders for $10.00 per share in cash, after which Agiliti will no longer be a publicly-traded company.

The merger investigation is focused on whether the merger is adequate and fair to Agiliti shareholders, as well as whether Agiliti’s board of directors or executive management may have breached their fiduciary duties in agreeing to take Agiliti private.

INVESTORS OF AGILITI STOCK ARE ENCOURAGED TO CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C.

SHAREHOLDERS OF AGILITI ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE AGILITI MERGER INVESTIGATION AND POTENTIAL LEGAL CLAIMS.